Trial Profile

Phase 2 Study of Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nimotuzumab (Primary) ; Temozolomide
Indications Brain cancer
Focus Adverse reactions

Most Recent Events

14 Oct 2018 Planned End Date changed from 1 Aug 2017 to 1 Aug 2019.
14 Oct 2018 Planned primary completion date changed from 1 Jan 2017 to 1 Aug 2019.
31 Mar 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com